



FOR IMMEDIATE RELEASE: ALEXANDRIA, VA, July 22, 2026: The Coalition Against Socialized Medicine (CASM), a broad coalition of leading conservative groups, has issued the following statement regarding the [CLEAR LABELS Act](#) (S. 3788).

“CASM urges the Senate Committee on Health, Education, Labor, and Pensions to oppose the CLEAR LABELS Act. Rather than improving drug safety or patient care, this legislation would impose unnecessary labeling requirements on prescription drug manufacturers, mandating the public disclosure of sensitive manufacturing and sourcing information.

“S. 3788 would create legal and regulatory uncertainty for innovators by establishing new compliance requirements without directing the Food and Drug Administration (FDA) to establish clear rules to govern compliance. Without clear guidance, manufacturers risk facing misbranding violations and steep financial penalties, undermining incentives to develop new products.

“The FDA already collects sensitive manufacturing information through existing regulatory processes; therefore, making this information publicly available through S. 3788 could expose critical supply chain data to foreign adversaries, like China. Enabling our competitors to have access to this information would compromise America’s competitive advantage in biopharmaceutical innovation and threaten supply chain resilience, without delivering meaningful public health benefit.

“CASM urges members of the Committee to reject legislation that imposes unnecessary regulatory mandates—like S. 3788—and instead advance policies that promote American medical innovation, strengthen intellectual property rights, and ensure patients have continued access to safe, effective treatments.”